2024 Summit and Summit KOL EASL Abstracts

Abstract Lead Author	Summit Contributor	Page	Title
Vlad Ratziu	Stephen A Harrison, Jorn M Schattenberg, Rebecca Taub, Dominic Labriola, Brandon Hill	S141	Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH/MASH serial liver biopsy study
Terry Cheuk-Fung Yip	Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagstrom, Jerome Boursier, Jose Luis Calleja Panero, George Boon Bee Goh, Wah-Kheong Chan, Rocio Gallego-Duran, Arun J Sanyal, Victor de Ledinghen, Philip N Newsome, Jiangao Fan, Laurent Castera, Michelle Lai, Stephen A Harrison, Celine Fournier-Poizat, Grace Lai-Hung Wong, Grazia Pennisi, Angelo Armandi, atsusho Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-Loup, Elba Lop Herrera, Kevin Kim Jun Teh, Carmen Lara-Romero, Amon Asgharpour, Sara Mahgoub, Chan Mandy, Clemence M Canivet, Manuel Romero-Gomez, Seung Up Kim, Vincent Wai-Sun Wong	S2	Prognostic significance of a change in liver stiffness measurements by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Julie Dubourg	Stephen A Harrison, Mazen Noureddin, Naim Alkhouri, Jorn M Schattenberg, Sophie Jeannin, Vlad Ratziu, Michael Charlton	S37	Association between advanced fibrosis and NASH-CRN activity score (NAS) components: combined data from multiple therapeutic trials including more than 10,000 patients
Elba Llop Herrera	Huapeng Lin, Hye Won Lee, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Haggstorm, Jerome Boursier, George Boon Bee Goh, Chan Wah Kheong, Rocio Gallego-Durn, Arun J Sanyal, Victor de Ledinghen, Philip N Newsome, Jiangao Fan, Laurent Castera, Michelle Lai, Stephen A Harrison, Celine Fournier-poizat, Grace Lai-Hung Wong, Grazia Pennisi, Angelo Armandi, Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-loup, Kevin Kim Jun Teh, Caren Lara-Romero, Amon Asgharpour, Sara Mahgoub, Chan Mandy, Clemence M Canivet, Manuel Romero-Gomez, Seung Up Kim, Vincent Wai-Sun Wong, Jose Luis Calleja Panero	S38	Validation of the Baveno VII 'rule of 5' in a real-life multicentre cohort of patients with metabolic dysfunction associated steatotic liver disease
Rohit Loomba	Eduardo Martins, Katharine Grimmer, Wen-Wei Tsai, Marie O'Farrell, William McCulloch, George Kemble, Pierre Bedossa, Jose	S4	Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week international, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis

	Cpbiella, Eric lawitz, Madhavi Rudraraju, Stephen A Harrison		
Julie Dubourg	Vlad Ratziu, Jorn M Schattenberg, Mazen Noureddin, Naim Alkhouri, Michael Charlton, Stephen A Harrison	S463	The infamous ballooned hepatocyte-fact or fiction: combined data from multiple therapeutic trials including more than 10,000 patients
Dean Tai	David E Kleiner, Andrew D Clouston, Zachary Goodman, Cynthia D Guy, Elizabeth M Brunt, Carolin Lackner, Dina G Tiniakos, Aileen Wee, Matthew Yeh, Wei Qiang Leow, Elaine Chng, Yayun Ren, George Boon Bee Goh, Elizabeth E Powell, Mary E Rinella, Arun J Sanyal, Brent A Neuschwander-Tetri, Zobair Younossi, Michael Charlton, Vlad Ratziu, Stephen A Harrison, Quentin M Anstee	S467	Ballooning: AI- based ballooned hepatocyte detection and quantification by second harmonic generation/two photon excitation microscopy
Julie Dubourg	Stephen A Harrison, Vlad Ratziu, Jorn M Schattenberg, Naim Alkhouri, Mazen Noureddin, Michael Charlton	S481	Association of plasma Magnesium with MASH and cirrhosis: combined data from multiple therapeutic trials including more than 10,000 patients
Julie Dubourg	Stephen A Harrison, Naim Alkhouri, Mazen Noureddin, Jorn M Schattenberg, Sophie Jeannin, Vlad Ratziu, Michael Charlton	S504	Clinical, biological and imaging predictors of at-risk MASH: combined data from multiple therapeutic trials including more than 10,000 patients
Jorn M Schattenberg	Rohit Loomba, Rebecca Taub, Dominic Labriola, Mazen Noureddin, Vlad Ratziu, Stephen A Harrison	S505	Non-invasive predictive markers of resmetirom biopsy response

Hanna Pulaski	Hypatia Hou, Murray Resnick, Stephen A Harrison, Arun J Sanyal, Vlad Ratziu, Alastair Burt, Pierre Bedossa, Michael Montalto, Katy Wack	S507	Artificial intelligence-based measurement of non-alcoholic steatohepatitis is an accurate tool for clinical trial enrollment and end point assessment
Mazen Noureddin	Naim Alkhouri, Vlad Ratziu, Jorn M Schattenberg, Michael Charlton, Julie Dubourg, Stephen A Harrison	S507	Clinical, biological and imaging predictors of advanced fibrosis (F3-F4): Combined data from multiple therapeutic trials including more than 10,000 patients
Naim Alkhouri	Mazen Noureddin, Jorn M Schattenberg, Vlad Ratziu, Michael Charlton, Julie Dubourg, Stephen A Harrison	S511	Performance of non-invasive test to diagnose cirrhosis in MASH trials: combined data from multiple therapeutic trials
Naim Alkhouri	Mazen Noureddin, Jorn M Schattenberg, Vlad Ratziu, Michael Charlton, Julie Dubourg, Stephen A Harrison	S511	The 2023 AASLD practice guidance for MASLD does not adequately risk stratify MASLD patients in the context of therapeutic trials
Kutbuddin Akbary	Dean Tai, Galvin Gan, Julie Dubourg, Stephen A Harrison	S515	Assessment of fibrosis change rate in placebo arm of metabolic dysfunction-associated steatohepatitis drug trial based on pathologist readouts and fibrosis continuous values
Giulia Angelini	Sara Russo, Erminia Lembo, Ornella Verrastro, Caterine Guidone, Antonio Liguori, Stephen A Harrison, Aldo Trylesinski, Luca Miele, Gertrude Mingrone	S516	HeparDx (by Metadeq, Inc.) is a reliable biomarker-based non-invasive test for MASH, capable of detecting the presence of inflammation and ballooning
Sarah Browne	Stephen A Harrison, John Suschak, Matthew McDaniel, Zackary Kenz, Shaheen Tomah, Jonathan Kasper, M Scot Roberts, Scott Siler, M Scott Harris	S517	Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model
Mazen Noureddin	Sophie Jeannin, Niam Alkhouri, Vlad Ratziu, Jorn M Schattenberg,	S518	Clinical and biological predictors of liver fat content>8% as assessed by MRI-PDFF:

	Michael Charlton, Julie Dubourg, Stephen A Harrison		combined data from multiple therapeutic trials including more than 10,000 patients
Vlad Ratziu	Louis Petitjean, Raluca Pais, Judith Aron-Wisnewsky, Li Chen, Leila Kara, Frederic Charlotte, Pierre Bedossa, Mathieu Petitjean	S533	AI-assisted, quantitative digital pathology-based continuous fibrosis scores perform better than conventional pathology in documenting fibrosis reduction
Giulia Angelini	Sara Russo, Federico Biscetti, Andrea Flex, Jerome Boursier, Sven Francque, Aldo Trylesinski, Stephen A Harrison, Gertrude Mingrone	S545	PLIN2 is a specific marker for liver related disease
Timothy Kendall	Stephen A Harrison, Dean Tai, Elaine Chng, Yayun Ren, Jonathan Fallowfield	S56	Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease
Joseph Rubinsztain	Naim Alkhouri, Karen Taub, Stephen A Harrison, Devon Y Chang, Mazen Noureddin	S576	External validation of machine learning model (MASML) adjusted for prevalence for determining the histologic severity of MASLD in a large cohort of patients with biopsy-proven disease
Joseph Rubinsztain	Maze Noureddin, Karen Taub, Devon Y Chang, Stephen A Harrison, Naim Alkhouri	S579	Comparison of machine learning model (MASML), VCTE, and FIB-4 scores for predicting the presence of MASLD in a large cohort of patients in the U.S. using the NHANES database
David A Fraser	Naim Alkhouri, Hilde Steineger, Mazen Noureddin, Quentin M Anstee, Stephen A Harrison	S603	Effect of icosabutate, a duel free fatty acid receptor-1 and -4 agonist, on elevated non-invasive markers of liver injury, fibrosis and glycemic control in type 2 diabetic MASH patients and F1-F3 fibrosis
Arun J Sanyal	Manal F Abdelmalek, Kris V Kowdley, Naim Alkhouri, Stephen A Harrison, Jorn M Schattenberg, Mildred D Gottwald, Shibao Feng, Germaine D Agollah, Cynthia L Hartsfield, Hank	S607	Pegozafermin added to background GLP-1 therapy in patients with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: ENLIVEN 48-week extension data

	Mansbach, Maya Margalit, Rohit Loomba		
Lois Lee	Stephen A Harrison, Niam Alkhouri, Mazen Noureddin, Eric Lawitz, Kris V Kowdley, Rohit Loomba, Christopher Jones, Erin Quirk	S607	TERN-501, a highly selective thyroid hormone receptor B agonist, significantly improved MRI-PDFF, cT1, and liver volume in clinically relevant patient populations with presumed MASH: subgroup analyses from a 12-week phase 2a trial
Naim Alkhouri	Stephen A Harrison, Eric Lawitz, Kris V Kowdley, Rohit Loomba, Lois Lee, Christopher Jones, Erin Quirk, Mazen Noureddin	S609	Sex hormone binding globulins an effective predictor of treatment response to TERN-501, a potent, highly selective thyroid hormone receptor B agonist: post-hoc analyses from a 12-week phase 2a trial
Jorn M Schattenberg	Quentin M Anstee, Stephen A Harrison, Mazen Noureddin, Rebecca Taub, Dominic Labriola, Jan Priel, Krishna Padmanabhan	S611	Using machine learning models to predict baseline fibrosis stage in patients from phase 3 resmetirom trials (MAESTRO-NAFLD and MAESTRO-NASH)
Erik Tillman	Doreen Chan, Reshma Shringarpure, Diana Leeming, Morten Karsdal, Stephen A Harrison, Andrew Cheng, Kitty Yale, Tim Rolph	S612	Efruxifermin treatment improved collagen biomarkers consistent with remodeling of the extracellular matrix in patients with F2-F3 fibrosis due to MASH
Leigh MacConell	Stephen A Harrison, Guy Neff, Nadege Gunn, Abigail Flyer	S614	Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM
Guy Neff	Stephen A Harrison, Nedege Gunn, Abigail Flyer, Kui Liu, Alexander Liberman	S618	Time course of onset, incidence and prevalence of gastrointestinal adverse events with HTD1801 (Berberine Ursodeoxycholate) in patients with MASH and T2DM
Jorn M Schattenberg	Naim Alkhouri, Mazen Noureddin, Vlad Ratziu, Michael Charlton, Julie Dubourg, Stephen A Harrison	S648	Exploring racial, ethnic, and demographics representativeness in MASH clinical trials: combined data from multiple therapeutic trials including more than 10,000 patients

Mazen Noureddin	Jorn M Schattenberg, Rohit Loomba, Rebecca Taub, Dominic Labriola, Stephen A Harrison	S71	Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial
Rohit Loomba	Manal F Abdelmalek, Kris V Kowdley, Naim Alkhouri, Stephen A Harrison, Jorn M Schattenberg, Mildred D Gottwald, Shibao Feng, Germaine D Agollah, Cynthia L Hartsfield, Hank Mansbach, Maya Margalit, Arun J Sanyal	S72	Week 48 results from the phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis
Jorn M Schattenberg	Stephen A Harrison, Rebecca Taub, Dominic Labriola, Hang Zhang, Elaine Chng, Yayun Ren, Dean Tai	S76	Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH
Vlad Ratziu	Stephen A Harrison, Juan P Frais, Guy Neff, Gary Abrams, Kathryn Jean Lucas, William Sanchez, Sudhanshu Gogia, Muhammad Y sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Matthew Minerva, Kimberly Barrett, Reshma Shringarpure, Erik Tillman, Timm Rolph, Andrew Cheng, Kitty Yale	S8	Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-0F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)

Winston Dunn	Naim Alkhouri, Terry Cheuk-Fung Yip, Lautent Castera, Marina Takawy, Leon Adams, Nipun Verma, Juan Pablo Arab, Syed-Mohammed Jafri, Bihui Zhong, Julie Dubourg, Vincent Chen, Ashwani K Singal, Luis Antonio Diaz, Nicholas Dunn, Rida Nadeem, Vincent Wai-Sun Wong, Manal F Abdelmark, Zhengyi Wang, Ajay Kumar Duseja, Yousef Almahanna, Amani Bajunayd, Haya A Omeish, Junzhao Ye, Stephen A Harrison, Grace Lai-Hung Wong, Marco Arrese, Sage Robert, Congxiang Shao	S84	Enhancing prediction of moderate fibrosis in MASLD patients for Resmetirom treatment via Machine learning
Julie Dubourg	Stephen A Harrison, Sophie Jeannin Megnien, Larissa Goli, Mazen Noureddin, Naim Alkhouri, Jorn M Schattenberg, Vlad Ratziu	S88	Performance of AASLD, AGA, AACE guidelines to identify patients for resmetirom treatment: pooled dataset including more than 4,000 patients with liver biopsy